Long-Term Side Effects of Tyrosine Kinase Inhibitors
in Chronic Myeloid Leukemia.
Knowlden et al., "The EGFR-selective tyrosine kinase inhibitor
ZD1839 ('Iressa') is an effective inhibitor of tamoxifen-resistant breast cancer growth," European Journal of Cancer, vol.
VEGF/VEGFR axis can be therapeutically targeted either with antibodies aimed at the soluble extracellular ligands or with small molecule inhibitors (tyrosine kinase inhibitors
, TKIs) which block the intracellular domains of VEGFRs.
With the advent of tyrosine kinase inhibitors
with efficacy against only specific mutations, detecting these mutations has become increasingly important in the clinical laboratory setting.
Cutaneous adverse side effects including hand- foot syndrome caused by various chemotherapeutic agents including the relatively specific tyrosine kinase inhibitors
like sunitinib should be recognized early and managed aggressively as it is associated with decline in function and quality of life in already disturbed cancer victim.
Briefly, approximately 20% to 30% of lung adenocarcinomas contain an EGFR-activating mutation that predicts response to therapy with EGFR tyrosine kinase inhibitors
, such as erlotinib.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
This Phase 1 trial is a multi-center, open-label study testing the safety, durability, and tolerability of OTX-TKI, a bioresorbable hydrogel fiber implant formulated with a tyrosine kinase inhibitor
delivered by intravitreal injection to patients with wet AMD.
The US Food and Drug Administration (FDA) has granted priority review to Switzerland-based Roche for two of its cancer drugs, the selective tyrosine kinase inhibitor
Entrectinib (RXDX-101) and the anti-CD79b antibody drug conjugate (ADC) polatuzumab vedotin, it was reported yesterday.
Food and Drug Administration (FDA) has approved LORBRENA lor-BREN-ah (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor
(TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Through the acquisition, Celgene gains a highly-selective Brutona[euro](tm)s tyrosine kinase inhibitor
which is presently in Phase I development as well as Avilaa[euro](tm)s Avilomics protein silencing platform.
All of the patients enrolled in the phase III trial had epidermal growth factor receptor (EGFR) mutations that were sensitive to the tyrosine kinase inhibitor